Form 4: Zevra Therapeutics Director John Bode Granted 30,000 Stock Options as Compensation

Zevra Therapeutics, Inc. director John B. Bode was granted 30,000 stock options with an exercise price of $8.62 as part of his compensation for board service, vesting over the next year or upon specific events.

Summary

• John B. Bode, a Director of ZEVRA THERAPEUTICS, INC. (ZVRA), was granted 30,000 stock options on May 29, 2025.
• The options have an exercise price of $8.62 per share, which was the closing price of ZVRA's common stock on the Nasdaq Global Select Market on the grant date.
• These options were awarded as compensation for Mr. Bode's service on the Issuer's board of directors, in accordance with the company's tenth amended and restated non-employee director compensation policy.
• The options will vest 100% on the earliest of: the first anniversary of the grant date (May 29, 2026), one day prior to the first annual stockholders meeting after the grant date, or immediately prior to a change in control of the Issuer, contingent on Mr. Bode's continued service.
• Following this transaction, Mr. Bode beneficially owns 30,000 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The document reports a standard, expected compensation grant to a director, which is a neutral to slightly positive event as it aligns director interests with shareholders. There are no negative surprises or significant positive catalysts, hence a moderately positive score.

Positives

• The grant of stock options to Director John B. Bode aligns his interests with those of shareholders, as the value of his compensation is tied to the company's stock performance.
• The options were granted at the closing market price of $8.62, indicating a standard compensation practice rather than a discounted issuance.
• The vesting schedule encourages continued service from a board member, providing stability in governance.

Negatives

• There are no direct negative financial implications for the company from this specific Form 4 filing, as it details a standard compensation grant.

Risks

• The value of the stock options is subject to the future performance of ZEVRA THERAPEUTICS, INC.'s common stock; if the stock price does not rise above the exercise price of $8.62, the options may expire worthless.
• The vesting of the options is contingent on the reporting person's continued service, meaning the options could be forfeited if service ceases before vesting conditions are met.

Future Outlook

The stock options granted to Director John B. Bode are subject to a vesting schedule, with 100% vesting on the earliest of the first anniversary of the grant date (May 29, 2026), one day prior to the first annual stockholders meeting after the grant date, or immediately prior to a change in control of the Issuer, contingent on his continued service. This indicates a future commitment and potential for Mr. Bode to exercise these options, impacting the company's outstanding share count if exercised.

Industry Context

The grant of stock options to non-employee directors is a common practice across various industries, including the biotechnology and pharmaceutical sectors where Zevra Therapeutics operates. This form of compensation is widely used to attract and retain qualified board members and to align their financial interests with the long-term performance of the company and its shareholders.

Comparison to Industry Standards

• The practice of granting stock options as compensation for non-employee directors is a standard corporate governance practice, comparable to companies like Biogen Inc. (BIIB) or Gilead Sciences, Inc. (GILD) which also utilize equity-based compensation to align director interests with shareholder value.
• The exercise price being equal to the closing market price on the grant date ($8.62) is a typical and transparent approach for such grants, consistent with best practices to avoid immediate dilution or perceived preferential treatment.
• The vesting schedule, tied to continued service and accelerated vesting upon a change in control, is also a common feature in director compensation plans, similar to those seen in many publicly traded companies across the S&P 500, ensuring retention and providing a clear exit incentive in M&A scenarios.

Corporate Governance

Related Party Transactions

• The grant of 30,000 stock options to John B. Bode, a director of ZEVRA THERAPEUTICS, INC., constitutes a related party transaction as it involves compensation provided by the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholders by tying his compensation to the company's stock performance. Potential future exercise of options could lead to minor dilution, but this is a standard aspect of equity compensation plans.
• Management/Employees: No direct impact on other management or employees mentioned in this filing.
• Board of Directors: Reinforces the compensation structure for non-employee directors, potentially aiding in retention and attraction of qualified board members.

Next Steps

• The stock options granted to John B. Bode will vest on the earliest of May 29, 2026, one day prior to the first annual stockholders meeting after the grant date, or immediately prior to a change in control of ZEVRA THERAPEUTICS, INC., subject to his continued service.
• Upon vesting, John B. Bode will have the right to exercise these options to acquire 30,000 shares of ZVRA common stock at the exercise price of $8.62 per share.

Key Dates

Recommendation

Keywords

Zevra Therapeutics, ZVRA, SEC Form 4, Stock Options, Director Compensation, Equity Compensation, John B. Bode, Corporate Governance, Insider Transaction